Sunday, September 29, 2024
The biopharmaceutical oncology company Vidac Pharma (WKN: A3DTUQ | ISIN: GB00BM9XQ619 | Ticker Symbol: T9G) has reported several successes this year. At the end of March 2024, the company received approval from the Japanese Patent Office for its...
Monday, September 16, 2024
Those interested in investing in promising biotech small-caps should keep Vidac Pharma on the radar. Despite its manageable size, the Company is already in the clinical development phase. The best-known product, VDA-1275, is the focus of interest...
Wednesday, September 11, 2024
Vidac Pharma shares have gained over 23% in the past four weeks. Driven by strong study data from the biotech company focused on fighting cancer, analysts even see the potential for multiplication. Such euphoria has been absent at Bayer for some...
Wednesday, September 04, 2024
Vidac Pharma, a listed company in the clinical development phase, offers an exciting and promising prospect. Vidac Pharma's latest product, VDA-1275, is at the center of interest following a technical report. This innovative drug candidate for the...
Thursday, August 29, 2024
The new technology being developed by Vidac Pharma, a company founded in 2012 and led by Prof. Max Herzberg, one of the founding fathers of the Israeli life sciences industry, is groundbreaking. Vidac Pharma is researching drugs designed to help...
Wednesday, August 07, 2024
Among the biotech small-cap stocks, Vidac Pharma has recently made headlines. The British-Israeli company has recently published promising results of its studies with the promising compound VDA-1275 in several mouse and human cellular organoid...
Friday, August 02, 2024
A mega rally could start here, at least according to analysts who analyzed the recently published results of tests with next-generation drug candidates in human and murine tumour models. According to the analysis, Sphene Capital sees a price target...
Friday, July 05, 2024
With around 20 million cancer diagnoses worldwide each year, innovative therapeutic approaches are urgently needed. Companies such as Vidac Pharma are currently developing new ways of treating cancer that could lead to a groundbreaking...
Saturday, June 22, 2024
We have reported several times on Vidac Pharma plc in recent weeks. The interest in the share is enormous for a penny stock, with over 200,000 shares changing hands at times. The Company has just announced that the US Patent and Trademark Office...
Thursday, June 13, 2024
The biopharmaceutical company Vidac Pharma, which specializes in developing innovative cancer treatments, has recently achieved a significant milestone. On June 3, the Company was awarded a key patent for its group of molecules by the US Patent and...
Wednesday, May 29, 2024
FinanzNachrichten provides financial news and updates specifically related to Vidac Pharma Holdings PLC. It covers the company's stock performance, recent financial news, market analysis, and any significant corporate announcements. The page serves...
Wednesday, May 29, 2024
Vidac Pharma has not yet broken out of its sideways movement, but this is likely only a matter of time. The London-based biotech company is making good progress in cancer research and has been traded as a takeover candidate, especially since...
Thursday, May 09, 2024
There is hope on the horizon for biotech investors, according to news | financial, even if a rally in the Nasdaq Biotech Index late last year did not persist in 2024. Tough refinancing conditions have been holding the market back, according to the...
Monday, April 29, 2024
Oncology is on the brink of a golden era. Driven by an increase in cancer cases and impressive scientific advances, including gene and immunotherapies, a billion-dollar market with immense growth prospects is emerging. The increasing demand for...
Monday, April 22, 2024
UK and Israel-based Vidac Pharma plc (STU: T9G, WKN: A3DTUQ, ISIN: GB00BM9XQ619) is another clinical-stage biopharmaceutical company developing first-in-class oncology and oncodermatology therapies. Its breakthrough new technology, which corrects a...
Wednesday, April 17, 2024
The biopharmaceutical company Vidac Pharma (WKN: A3DTUQ | ISIN: GB00BM9XQ619 | Ticker symbol: T9G), which is based in Israel and the UK, received notification of approval for its drug candidate VDA-1275 from the Japanese Patent Office at the end of...
Monday, April 08, 2024
Since the onset of the COVID-19 pandemic, there has been little movement in the biotech sector. However, after a challenging year in 2023, the sector was at least able to start the new year on a solid footing. The surprising takeover of MorphoSys...